Skip to main content
SpringerLink
Log in

Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus

  • Drug Development
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Type 2 diabetes mellitus is characterized by insulin resistance, impaired glucose-induced insulin secretion, and inappropriately elevated glucagon levels which eventually result in hyperglycemia. The currently available treatment modalities for type 2 diabetes are often unsatisfactory in getting patients to glycemic goals, even when used in combination, and therefore many patients develop microvascular and macrovascular diabetic complications. Additionally, these treatment modalities are often limited by inconvenient dosage regimens and safety and tolerability issues, the latter including hypoglycemia, bodyweight gain, edema, and gastrointestinal intolerance. There is, therefore, a need for new and more efficacious agents, targeting not only treatment, but also prevention of the disease, its progression, and its associated complications.

Recently, an entirely new therapeutic option for the treatment of type 2 diabetes has become available in the US (since October 2005) and in Europe (since May 2007): the incretin-based therapies. The incretin-based therapies fall into two different classes: (i) incretin mimetics, i.e. injectable peptide preparations with actions similar to the natural incretin hormones; and (ii) the incretin enhancers, i.e. orally available agents that inhibit the degradation of the incretin hormones in the body and thereby increase their plasma levels and biologic actions. This article focuses on the incretin mimetics and outlines the scientific basis for the development of glucagon-like peptide-1 (GLP-1) analogs, reviews clinical experience gained so far, and discusses future expectations for long-acting forms of GLP-1 analogs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004; 47: 357–66

    Article  PubMed  Google Scholar 

  2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409–39

    Article  PubMed  CAS  Google Scholar 

  3. Vilsbøll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115–21

    Article  PubMed  Google Scholar 

  4. Nauck MA, Bartels E, Orskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912–7

    Article  PubMed  CAS  Google Scholar 

  5. Hvidberg A, Nielsen MT, Hilsted J, et al. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994; 43: 104–8

    Article  PubMed  CAS  Google Scholar 

  6. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153–65

    Article  PubMed  CAS  Google Scholar 

  7. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004; 47: 806–15

    Article  PubMed  CAS  Google Scholar 

  8. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824–30

    Article  PubMed  CAS  Google Scholar 

  9. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738–42

    Article  PubMed  CAS  Google Scholar 

  10. Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 1998; 41(10): 1180–6

    Article  PubMed  CAS  Google Scholar 

  11. Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull 2004; 51: 364–70

    PubMed  Google Scholar 

  12. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126–31

    Article  PubMed  CAS  Google Scholar 

  13. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952–7

    Article  PubMed  CAS  Google Scholar 

  14. Vilsbøll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220–4

    Article  PubMed  Google Scholar 

  15. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546–53

    Article  PubMed  CAS  Google Scholar 

  16. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52

    Article  PubMed  CAS  Google Scholar 

  17. Vilsbøll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609–13

    Article  PubMed  Google Scholar 

  18. Kjems LL, Holst JJ, Volund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380–6

    Article  PubMed  CAS  Google Scholar 

  19. Vilsbøll T, Krarup T, Madsba S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111–9

    Article  PubMed  Google Scholar 

  20. Hojbjerg P, Vilsbøll T, Knop FK, et al. Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type 2 diabetes [abstract no. 373]. Diabetes 2007; 56: A373

    Article  Google Scholar 

  21. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741–4

    Article  PubMed  CAS  Google Scholar 

  22. Deacon CF, Danielsen P, Klarskov L, et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50: 1588–97

    Article  PubMed  CAS  Google Scholar 

  23. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402–5

    PubMed  CAS  Google Scholar 

  24. Thorens B, Porret A, Buhler L, et al. Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678–82

    Article  PubMed  CAS  Google Scholar 

  25. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006; 49(4): 706–12

    Article  PubMed  CAS  Google Scholar 

  26. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155–61

    PubMed  CAS  Google Scholar 

  27. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173–81

    PubMed  CAS  Google Scholar 

  28. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194–206

    Article  PubMed  CAS  Google Scholar 

  29. Buse JB, MacConell L, Stonehouse A, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008 Jan; 24(1): 275–86

    PubMed  Google Scholar 

  30. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559–69

    PubMed  CAS  Google Scholar 

  31. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259–67

    Article  PubMed  CAS  Google Scholar 

  32. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195–202

    Article  PubMed  CAS  Google Scholar 

  33. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608–10

    Article  PubMed  Google Scholar 

  34. Standards of medical care in diabetes. Diabetes Care 2005; 28Suppl. 1: S4–36

    Google Scholar 

  35. Nauck MA, Hompesch M, Filipczak R, et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114: 417–23

    Article  PubMed  CAS  Google Scholar 

  36. Garber A, Henry R, Ratner R, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with glimepiride: all as monotherapy in type 2 diabetes [abstract no. 07-LB]. American Diabetes Association 68th Scientific Sessions; 2008 Jun 6–10; San Francisco (CA)

  37. Marre M, Shaw J, Brandie M, et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes [abstract no. 13-OR]. American Diabetes Association 68th Scientific Sessions; 2008 Jun 6–10; San Francisco (CA)

  38. Nauck MA, Frid A, Hermansen K, et al. Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin [abstract no. 504-P]. American Diabetes Association 68th Scientific Sessions; 2008 Jun 6–10; San Francisco (CA)

  39. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes [abstract no. 536-P]. American Diabetes Association 68th Scientific Sessions; 2008 Jun 6–10; San Francisco (CA)

  40. Novo Nordisk. To evaluate the effect of liraglutide versus glimepiride (Amaryl®) on haemoglobin Alc (LEAD 3) [clinicaltrials.gov identifier: NCT00294723; online]. Available from URL: http://www.clinicaltrials.gov/ct2/search [Accessed 2008 Jun 24]

  41. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487–93

    Article  PubMed  CAS  Google Scholar 

  42. Eli Lilly and Company. Investigational once-weekly exenatide demonstrated statistical superiority in glucose control compared to Byetta in head-to-head study. 2007 Oct 31 [media release; online]. Available from URL: http://www.what-snewinpharma.com/pages/PRdetail.aspx?articleId=17975 [Accessed 2008 May 1]

  43. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes [abstract no. 107-OR]. American Diabetes Association 68th Scientific Sessions; 2008 Jun 6-10; San Francisco (CA)

Download references

Acknowledgments

Tina Vilsbøll has worked as a consultant for and received lecture fees from Novo Nordisk, Novartis, Merck Sharp & Dohme, and Eli Lilly. She was previously on the Advisory Board for Novartis and is currently on the Advisory Board for Merck Sharp & Dohme. Filip Knop has received lecture fees from Merck Sharp & Dohme. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK-2900, Hellerup, Denmark

    Tina Vilsbøll & Filip K Knop

Authors
  1. Tina Vilsbøll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filip K Knop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina Vilsbøll.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vilsbøll, T., Knop, F.K. Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus. BioDrugs 22, 251–257 (2008). https://doi.org/10.2165/00063030-200822040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200822040-00004

Keywords

Search

Navigation